Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Société Générale M&A Activity 2020

May 7, 2020

1671_mrq_2020-05-07_3d531781-afb4-4936-9bb6-216555f4bc59.html

M&A Activity

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 2551M

Societe Generale SA

07 May 2020

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1) Société Générale S.A.
Company dealt in Allergan plc
Class of relevant security to which the dealings being disclosed relate (Note 2) US$0.0001 ordinary shares
Date of dealing 06/05/2020

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long Short
Number (%) Number (%)
(1) Relevant securities 2,737,782 0.83 77,186 0.02
(2) Derivatives (other than options) 0 0.00 2,497,791 0.76
(3) Options and agreements to purchase/sell 58,500 0.02 0 0.00
Total *6,861,143 *2.08 2,574,977 0.78

* Include the holding of 4,064,861 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale Number of relevant securities Price per unit USD (Note 5)
Purchase 100 194.01
Purchase 100 195.53
Purchase 191 194.13
Purchase 49 193.89
Purchase 872 193.89
Purchase 100 195.79
Purchase 200 194.595
Purchase 1,182 193.89
Sale 100 194.65
Sale 14 194.93
Sale 12 194.72
Sale 100 194.47
Sale 100 194.63
Sale 1 194.37
Sale 100 194.59
Sale 100 195.7
Sale 100 195.76
Sale 100 195.92
Sale 100 195.8
Sale 1 194.36
Sale 99 194.36
Sale 100 194.59
Sale 93 194.7
Sale 7 194.7
Sale 100 195.85
Sale 100 195.45
Sale 100 194.72
Sale 100 195.49
Sale 100 195.33
Sale 100 195.02
Sale 100 195.92
Sale 100 195.85
Sale 100 195.81
Sale 10 195.41
Sale 90 195.41
Sale 100 195.87
Sale 100 195.35
Sale 100 194.48
Sale 200 194.54
Sale 100 195.78
Sale 100 195.985
Sale 100 195.5
Sale 100 195.01
Sale 100 195.65
Sale 100 195.77
Sale 100 194.58
Sale 200 193.89
Sale 100 195.52
Sale 100 194.02
Sale 100 195.79
Sale 100 193.94
Sale 100 195.49
Sale 49 194.15
Sale 100 194.71
Sale 100 194.91
Sale 100 195.74
Sale 100 195.58
Sale 100 195.38
Sale 100 194.37
Sale 100 194.5
Sale 15 194.68
Sale 100 194.61
Sale 100 195.3
Sale 100 194.48
Sale 200 195.58
Sale 100 195.48
Sale 100 194.78
Sale 100 194.78
Sale 100 194.78
Sale 49 194.11
Sale 100 194.57
Sale 100 194.81
Sale 31 194.79
Sale 16 194.57
Sale 43 194.02
Sale 2,287 195.73605
Sale 1,564 194.311573
Sale 220 194.723864
Sale 100 194.72
Sale 631 195.482108
Sale 100 195.47
Sale 692,200 193.89
Sale 126 194.692222
Sale 8 194.21
Sale 100 194.21
Sale 138 193.922464
Sale 215 194.110326
Sale 25,700 194.049549
Sale 1,250 194.153584
Total Purchases 2,794
Total Sales 730,669

(b)      Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit USD

(Note 5)
Equity Linked Swap Decreased short 692,200 193.89

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name,

e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name,

e.g. call option
Number of securities Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
Details Price per unit

(if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and 

any other person relating to the voting rights of any relevant securities under any option referred to 

on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to 

which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            Yes

Date of disclosure 07/05/2020
Contact name Société Générale - Disclosure team
Telephone number +33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap23

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL 

ACT, 1997, TAKEOVER RULES, 2013

DETAILS OF OPEN POSITIONS

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

OPEN POSITIONS (Note 1)

Product name,

e.g. call option
Written, or purchased Number of relevant securities to which the option or derivative relates Exercise price (Note 2) Type, e.g. American, European etc. Expiry date
Listed Put Option Sale 40,000 175 American options 15/01/2021
Listed Put Option Sale 18,500 190 American options 15/01/2021

Notes

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2.          For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rule 8 of the 

Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ISEKKOBQOBKKKPK